Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways.

Drugs R D

3 Gennaio Gen 2024 one year ago
  • Mapelli M, Mattavelli I, Salvioni E, Bonomi A, Capra N, Palermo P, Banfi C, Biondi ML, Agostoni P

N-terminal pro-B-type natriuretic peptide (NT-proBNP) and soluble interleukin 1 receptor-like 1 ST2 (sST2) are biomarkers used to grade heart failure with reduced ejection fraction (HFrEF) severity. Both are potential targets of HFrEF treatment, but the first is associated with the patient's hemodynamic status, while the second is more indicative of the inflammatory status and of myocardial fibrosis. The aim of this study was to assess the kinetics of these biomarkers after treatment with sacubitril/valsartan in HFrEF.

Reference: Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways.
Mapelli M, Mattavelli I, Salvioni E, Bonomi A, Capra N, Palermo P, Banfi C, Paolillo S, Biondi ML, Agostoni P. Drugs R D. 2023 Sep 13.

Go to PubMed